CN104672243B — 维格列汀降解杂质的制备方法
Assigned to China Resources Saike Pharmaceutical Co Ltd · Expires 2017-09-22 · 9y expired
What this patent protects
本发明公开了一种维格列汀降解杂质2‑(3‑羟基‑金刚烷‑1‑基)‑1‑亚胺基‑六氢吡咯并[1,2‑a]吡嗪‑4‑酮和2‑(3‑羟基‑金刚烷‑1‑基)‑六氢吡咯并[1,2‑a]吡嗪‑1,4‑二酮的制备方法。该方法使用维格列汀作为起始物料，经过高温降解、柱层析分离得到2‑(3‑羟基‑金刚烷‑1‑基)‑1‑亚胺基‑六氢吡咯并[1,2‑a]吡嗪‑4‑酮，再经与水反应和柱分离得到2‑(3‑羟基‑金刚烷‑1‑基)‑六氢吡咯并[1,2‑a]吡嗪‑1,4‑二酮。本发明的有益效果：本发明制备出了纯度大于97％的维格列汀降解杂质2‑(3‑羟基‑金刚烷‑1‑基)‑1‑亚胺基‑…
USPTO Abstract
本发明公开了一种维格列汀降解杂质2‑(3‑羟基‑金刚烷‑1‑基)‑1‑亚胺基‑六氢吡咯并[1,2‑a]吡嗪‑4‑酮和2‑(3‑羟基‑金刚烷‑1‑基)‑六氢吡咯并[1,2‑a]吡嗪‑1,4‑二酮的制备方法。该方法使用维格列汀作为起始物料，经过高温降解、柱层析分离得到2‑(3‑羟基‑金刚烷‑1‑基)‑1‑亚胺基‑六氢吡咯并[1,2‑a]吡嗪‑4‑酮，再经与水反应和柱分离得到2‑(3‑羟基‑金刚烷‑1‑基)‑六氢吡咯并[1,2‑a]吡嗪‑1,4‑二酮。本发明的有益效果：本发明制备出了纯度大于97％的维格列汀降解杂质2‑(3‑羟基‑金刚烷‑1‑基)‑1‑亚胺基‑六氢吡咯并[1,2‑a]吡嗪‑4‑酮和2‑(3‑羟基‑金刚烷‑1‑基)‑六氢吡咯并[1,2‑a]吡嗪‑1,4‑二酮的标准品。
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.